ASCO GU 2019 Kidney Cancer - Results from #20

Viewing 21-40 of 52 articles

ASCO GU 2019: RENAVIV: Pazopanib with or without Abexinostat in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

ASCO GU 2019: Gemcitabine Plus Axitinib in Patients with Sarcomatoid Type Renal Carcinoma

ASCO GU 2019: Novel Predictive Models of Early Death Less than One Year in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitors

ASCO GU 2019: Results of a Phase II Study to Evaluate the Safety and Efficacy of RX-0201 in Combination with Everolimus in Subjects with mRCC

ASCO GU 2019: A Phase II study of Cabozantinib as First-line Treatment in Metastatic Collecting Duct Carcinoma: The BONSAI Trial

ASCO GU 2019: Renal Function Preservation in Kidney Cancer: Current Techniques and Biomarkers

ASCO GU 2019: Non-Clear Cell Renal Cell Carcinoma: Jumping on the Immunotherapy Bandwagon

ASCO GU 2019: Risk Stratification After Resection of Localized Disease: Which Model to Use, and Why?

ASCO GU 2019: CB-839, A Glutaminase Inhibitor, in Combination with Cabozantinib in Patients with Clear Cell and Papillary Metastatic Renal Cell Cancer

ASCO GU 2019: Informing the Decision Using Clinical Trial Evidence - Localized Kidney Cancer

ASCO GU 2019: Safety and Efficacy of Nivolumab in Metastatic Renal Cell Carcinoma: Final Analysis from the NIVOREN GETUG AFU 26 Study

ASCO GU 2019: Phase Ib (COSMIC-021) Trial of Cabozantinib in Urothelial Carcinoma or Cabozantinib in Combination with Atezolizumab in patients with Urothelial Carcinoma, Castrate Resistant Prostate Cancer or Renal Cell Carcinoma

ASCO GU 2019: CANTATA: Randomized, International, Double-Blind Study of CB-839 Plus Cabozantinib versus Cabozantinib Plus Placebo in Patients with Metastatic Renal Cell Carcinoma

ASCO GU 2019: First-line Pembrolizumab Monotherapy for Advanced Non-Clear Cell Renal Cell Carcinoma: Results from KEYNOTE-427 Cohort B

ASCO GU 2019: Discussion on: The KEYNOTE-426 Study and the Subgroup Analysis from the JAVELIN Renal 101

ASCO GU 2019: The Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer, CALYPSO Study

ASCO GU 2019: Subgroup Analysis from JAVELIN Renal 101: Outcomes for Avelumab plus Axitinib versus Sunitinib in Advanced Renal Cell Carcinoma

ASCO GU 2019: Pembrolizumab Plus Axitinib versus Sunitinib as First-line Therapy for Locally Advanced or Metastatic Renal Cell Carcinoma: Phase III KEYNOTE-426 Study

ASCO GU 2019: Treatment-Free Survival after Discontinuation of First-Line Nivolumab Plus Ipilimumab or Sunitinib in Intention-to-Treat and IMDC Favorable-Risk Patients with Advanced Renal Cell Carcinoma from CheckMate 214

ASCO GU 2019: A Phase II Open-label Study of Cabozantinib in Patients with Advanced or Unresectable Renal Cell Carcinoma Pretreated with One Immune-Checkpoint Inhibitor: The BREAKPOINT Trial

1
2
3